Cyprotex - News
This site uses cookies. By continuing to browse the site you are agreeing to our use of cookies. Find out more here.

Final Results

Cyprotex PLC
("Cyprotex" or the "Company" or the "Group")

Final results for the year ended 31 December 2009

Resilient performance in difficult market for pre-clinical CRO's

Cyprotex PLC (AIM:CRX), the drug discovery technology and information company, today reports its final results for the year ended 31 December 2009. Cyprotex enables its customers to access secure, high quality Absorption, Distribution, Metabolism, Excretion / Toxicity (ADMET) data without incurring significant overheads. Its highly automated platform guarantees high throughput, reproducibility and rapid turnaround of ADMET data, setting new industry standards for this sector of the market.

Financial Highlights

· Revenues hit £5 million for second successive year at £5.00 million (2008: £5.18 million)

· Second year of profitability with operating profits at £0.46 million (2008: £0.57 million)

· Cash and cash equivalents up £0.49 million at £2.07 million

· Strong positive cash flow from operations at £0.90 million up £0.36 million

Operational Highlights

· Doubled number of strategic customers in 2009 (being customers contributing annual revenues in excess of £250,000 each) from three to six

· Won over twenty new customers

· Newly internally developed assays generated over £300,000 of revenues

· Investment in laboratory space and state of the art mass spectrometer secured new strategic customer

· Strategic alliance announced with Sygnature Chemical Services Limited, a leading provider of medicinal and computational chemistry services

· Launched Cloe® Gateway, our new web based portal for access to Cyprotex services

Steve Harris, Chairman of Cyprotex PLC, said:

"Cyprotex's results represent an impressive performance against a very difficult market currently for the pre-clinical CRO sector. Cyprotex continues to attract new customers, expand its offerings and is investing in new laboratories to service both the ADME and pre-clinical toxicology markets"

Download Cyprotex Final Results for year ended 31 December 2009


For further information:

Cyprotex PLC
Dr Anthony Baxter, Chief Executive Officer
John Dootson, Chief Financial Officer
Tel: +44 (0) 1625 505 100
ir@cyprotex.com
www.cyprotex.com

Execution Noble & Company
John Llewellyn-Lloyd
john.llewellyn-lloyd@execution-noble.com
Sam Reynolds
sam.reynolds@execution-noble.com
Tel: +44 (0) 20 7456 9191
www.execution-noble.com

Financial Dynamics
Ben Brewerton / Ben Atwell / John Dineen
Tel: +44 (0) 20 7831 3113
cyprotex@fd.com
www.fd.com

Contact us

News categories

Archives

Contact us to discuss your ADME Tox issues or request a quote

Telephone:
North America (East Coast): 888-297-7683
Europe: +44 1625 505100

 

or fill out the form below:

Please give details of the assays you are interested in. Where appropriate please specify one or more species (human, rat, mouse etc.), isoforms (CYP1A1,CYP1B1, etc) or other relevant details.

Close